ACT-500
/ Xiamen Amoytop Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 11, 2026
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Xiamen Amoytop Biotech Co., Ltd.
New P1 trial • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • APOB
February 18, 2026
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=72 | Completed | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Recruiting ➔ Completed
Trial completion • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis
April 08, 2025
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Xiamen Amoytop Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis
1 to 3
Of
3
Go to page
1